DIAGNOS will be Attending in San Francisco during the J.P. Morgan Health Care Conference Week to be held from January 10th to 13th, 2022
December 15 2021 - 9:00AM
Diagnos Inc. (“
DIAGNOS” or the
“
Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a
leader in early detection of critical health issues, announces
today that DIAGNOS will be in San Francisco during the J.P. Morgan
40th Annual Healthcare Conference events running from January 10th
to 13th, 2022 in San Francisco, California.
Forty years ago, J.P. Morgan launched Wall
Street’s premier investor conference focused exclusively on
companies defining the healthcare industry. The J.P. Morgan
Healthcare Conference brings industry leaders, emerging fast-growth
companies, and members of the investment community together in the
largest healthcare investment symposium to deliver presentations to
global investors. This year, J.P. Morgan expects more than 300
companies, both public and private. The conference brings together
thousands of investors and executives from around the world. It
continues to be one of the industry’s largest conferences of the
year.
DIAGNOS President & CEO, Andre Larente, will
be in attendance. The team will also include Pascal Nigen, Managing
Partner at Alpha Bronze. If there is interest in setting up a
meeting with CEO Andre Larente, please contact Pascal Nigen at
pnigen@alphabronzellc.com or + 1 (917) 385-2160.
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
Email: alarente@diagnos.ca
Nancy Massicotte
Corporate Communications
IR Pro Communications Inc.
Dir: +1 604-507-3377
TF: 1-866-503-3377
Email: nancy@irprocommunications.com
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024